Bernard Taylor is a senior advisor at Evercore.
Mr. Taylor was previously chairman and CEO of Evercore in Europe as well as a senior managing director after serving as chief executive of Braveheart, acquired in 2006 by Evercore.
In 1999, Mr. Taylor was joint chief executive of global investment banking, deputy chairman and chief executive of Robert Fleming & Co. When Chase Manhattan bought Fleming, he oversaw investment banking activities of the EMEA expansion as vice chairman and a member of the Chase Global Management Committee in New York. After Chase bought JPMorgan, Mr. Taylor remained as a JPMorgan vice chairman in Europe until 2005, when he founded Braveheart.
Select U.K. and international M&A transactions include advising The Wellcome Trust on the offer by Glaxo for Wellcome; Dresdner Bank on the offer for Kleinwort Benson; Northern Telecom on the acquisition of STC and on its joint ventures with both Daimler Benz and Lagardère Groupe; ING on the acquisition of Barings; and Matra Hachette on its missiles joint venture with British Aerospace.
Other notable deals advising include Aérospatiale Matra on the formation of European Aeronautic Defense & Space; Amersham on the sale to GE; the purchase of Schwarz Pharma by UCB; and the sale of Smiths Groups’ industries aerospace division to GE.
Mr. Taylor earned an M.A. from Oxford University (St. John’s College, where he is an Honorary Fellow) and is a Fellow of the Royal Society of Chemistry.